Evidence map›Paper›PMID 24668547›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014

Differential expression of histone deacetylase and acetyltransferase genes in gastric cancer and their modulation by trichostatin A.

Fernanda Wisnieski, Danielle Queiroz Calcagno, Mariana Ferreira Leal, Elizabeth Suchi Chen, Carolina Oliveira Gigek, Leonardo Caires Santos, Thaís Brilhante Pontes, Lucas Trevizani Rasmussen, Spencer Luiz Marques Payão, Paulo Pimentel Assumpção and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 47 citations in OpenAlex.

  1. The role of TLRs (microbe recognition receptor) in gastric cancer: An update.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  2. Review
  3. Genomic analyses identify 15 risk loci and revealProceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Gastric cancer: An epigenetic view.World journal of gastrointestinal oncology · 2022
    Review
  11. Differential regulation ofEpigenetics · 2022
    Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. KATapulting toward Pluripotency and Cancer.Journal of molecular biology · 2017
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Fernanda WisnieskiDisciplina de Genética, Departamento de Morfologia e Genética, Universidade Federal de São Paulo, Rua Botucatu, 740, São Paulo, 04023900, Brazil, fernandawis@yahoo.com.br.
Danielle Queiroz Calcagno
Mariana Ferreira Leal
Elizabeth Suchi Chen
Carolina Oliveira Gigek
Leonardo Caires Santos
Thaís Brilhante Pontes
Lucas Trevizani Rasmussen
Spencer Luiz Marques Payão
Paulo Pimentel Assumpção
Laércio Gomes Lourenço
Sâmia Demachki
Ricardo Artigiani
Rommel Rodríguez Burbano
Marília Cardoso Smith
Universidade Federal de São Paulo · BRUniversidade Federal do Pará · BRFaculdade de Medicina de Marília · BRUniversidade Sagrado Coração · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer is still the second leading cause of cancer-related death worldwide, even though its incidence and mortality have declined over the recent few decades. Epigenetic control using histone deacetylase inhibitors, such as trichostatin A (TSA), is a promising cancer therapy. This study aimed to assess the messenger RNA (mRNA) levels of three histone deacetylases (HDAC1, HDAC2, and HDAC3), two histone acetyltransferases (GCN5 and PCAF), and two possible targets of these histone modifiers (MYC and CDKN1A) in 50 matched pairs of gastric tumors and corresponding adjacent nontumors samples from patients with gastric adenocarcinoma, as well as their correlations and their possible associations with clinicopathological features. Additionally, we evaluated whether these genes are sensitive to TSA in gastric cancer cell lines. Our results demonstrated downregulation of HDAC1, PCAF, and CDKN1A in gastric tumors compared with adjacent nontumors (P < 0.05). On the other hand, upregulation of HDAC2, GCN5, and MYC was observed in gastric tumors compared with adjacent nontumors (P < 0.05). The mRNA level of MYC was correlated to HDAC3 and GCN5 (P < 0.05), whereas CDKN1A was correlated to HDAC1 and GCN5 (P < 0.05 and P < 0.01, respectively). In addition, the reduced expression of PCAF was associated with intestinal-type gastric cancer (P = 0.03) and TNM stages I/II (P = 0.01). The increased expression of GCN5 was associated with advanced stage gastric cancer (P = 0.02) and tumor invasion (P = 0.03). The gastric cell lines treated with TSA showed different patterns of histone deacetylase and acetyltransferase mRNA expression, downregulation of MYC, and upregulation of CDKN1A. Our findings suggest that alteration of histone modifier genes play an important role in gastric carcinogenesis, contributing to MYC and CDKN1A deregulation. In addition, all genes studied here are modulated by TSA, although this modulation appears to be dependent of the genetic background of the cell line.

Indexed as

Cell Line, TumorCyclin-Dependent Kinase Inhibitor p21Gene Expression Regulation, NeoplasticGenes, mycHistone Deacetylase 1Histone Deacetylase 2Histone Deacetylase 3Histone Deacetylase InhibitorsHistone DeacetylasesHumansHydroxamic Acidsp300-CBP-Associated Factorp300-CBP Transcription FactorsRNA, MessengerStomach NeoplasmsTranscriptional ActivationCDKN1A protein, humanCyclin-Dependent Kinase Inhibitor p21HDAC1 protein, humanHDAC2 protein, humanHistone Deacetylase 1Histone Deacetylase 2Histone Deacetylase 3Histone Deacetylase InhibitorsHistone DeacetylasesHydroxamic Acidsp300-CBP-Associated Factorp300-CBP Transcription FactorsRNA, Messengertrichostatin A

Identifiers

PMID24668547
OpenAlexW2125027849

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.